Advances in graft-versus-host disease biology and therapy
Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders,
but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past …
but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past …
Graft-versus-host disease
Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …
haematological malignant disorders and other life-threatening haematological and genetic …
[HTML][HTML] MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota
Graft-versus-host disease (GVHD) in the gastrointestinal (GI) tract is the principal
determinant of lethality following allogeneic bone marrow transplantation (BMT). Here, we …
determinant of lethality following allogeneic bone marrow transplantation (BMT). Here, we …
Pathophysiology of GvHD and other HSCT-related major complications
S Ghimire, D Weber, E Mavin, XN Wang… - Frontiers in …, 2017 - frontiersin.org
For over 60 years, hematopoietic stem cell transplantation has been the major curative
therapy for several hematological and genetic disorders, but its efficacy is limited by the …
therapy for several hematological and genetic disorders, but its efficacy is limited by the …
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation
M Edinger, P Hoffmann, J Ermann, K Drago… - Nature medicine, 2003 - nature.com
Mature donor T cells cause graft-versus-host disease (GVHD), but they are also the main
mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow …
mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow …
Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response
AC Court, A Le‐Gatt, P Luz‐Crawford, E Parra… - EMBO …, 2020 - embopress.org
Mesenchymal stem cells (MSCs) have fueled ample translation for the treatment of immune‐
mediated diseases. They exert immunoregulatory and tissue‐restoring effects. MSC …
mediated diseases. They exert immunoregulatory and tissue‐restoring effects. MSC …
Graft-versus-leukemia effects of transplantation and donor lymphocytes
HJ Kolb - Blood, The Journal of the American Society of …, 2008 - ashpublications.org
Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even
in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) …
in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) …
Graft-versus-host disease
WD Shlomchik - Nature Reviews Immunology, 2007 - nature.com
Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for
haematological malignancies and inherited disorders of blood cells, such as sickle-cell …
haematological malignancies and inherited disorders of blood cells, such as sickle-cell …
Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins
Y Eriguchi, S Takashima, H Oka… - Blood, The Journal …, 2012 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (SCT) is a curative therapy for various
hematologic disorders. Graft-versus-host disease (GVHD) and infections are the major …
hematologic disorders. Graft-versus-host disease (GVHD) and infections are the major …
Mouse models of graft-versus-host disease: advances and limitations
MA Schroeder, JF DiPersio - Disease models & …, 2011 - journals.biologists.com
The limiting factor for successful hematopoietic stem cell transplantation (HSCT) is graft-
versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated …
versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated …